Molecular imaging with positron emission tomography and computed tomography (PET/CT) for selecting first-line targeted treatment in metastatic breast cancer: a cost-effectiveness study

Our aim was to evaluate the potential cost-effectiveness of PET/CT with FES and (89)Zr-trastuzumab compared to pathology to select first-line targeted treatment in metastatic breast cancer (MBC) patients with non-rapidly progressive disease. A previously published and validated model was extended an...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Oncotarget
Główni autorzy: Koleva-Kolarova, Rositsa G., Greuter, Marcel J.W., Feenstra, Talitha L., Vermeulen, Karin M., de Vries, Erik F.J., Parkin, David, Buskens, Erik, de Bock, Geertruida H.
Format: Artigo
Język:Inglês
Wydane: Impact Journals LLC 2018
Hasła przedmiotowe:
Research Paper
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5929430/
https://ncbi.nlm.nih.gov/pubmed/29731987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24869
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy